Skip to main content


Product Description

Refining lung cancer heterogeneity analysis and predicting clinical endpoints through SoC CT acquisitions

Many therapeutic decisions in lung cancer are today based on techniques which provide information about the tumor mutational status from next generation sequencing (NGS) and the PD-L1 fraction of the tissue through immunohistochemistry (IHC), among others. Quibim is developing a new solution to work in combination with existing techniques to classify tumor mutational status, predict response to immune checkpoint inhibitors and overall survival from the analysis of the baseline CT scan.

Vendor Info


Avenida Aragรณn 30
13th floor, office I โ€“ J
46021, Valencia+34 961 243

Quibim designs pioneering tools that unlock imaging data to improve patient outcomes.

After years of intense research in imaging biomarkers, Quibim (QUantitative Imaging Biomarkers In Medicine) did the commercial launch and internationalization in 2021. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers. The business model is based on a platform marketed through SaaS for hospitals and value-based partnerships in life sciences that help to identify new market needs and create new algorithms.

Having expanded internationally and with a growing team, Quibim is now heading up to bring a new line of products based on predictive imaging biomarker panels.

<< return to products